GH * Overzicht aandelen Guardant Health, Inc., een oncologisch precisiebedrijf, levert bloed- en weefseltests, datasets en analyses in de Verenigde Staten en daarbuiten. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Guardant Health, Inc. Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Guardant Health Historische aandelenkoersen Huidige aandelenkoers US$731.50 52 Week Hoogtepunt US$731.50 52 Week Laag US$293.83 Bèta 1.28 1 maand verandering 0% 3 maanden verandering n/a 1 Jaar Verandering n/a 3 jaar verandering -58.39% 5 jaar verandering -52.19% Verandering sinds IPO -53.50%
Recent nieuws en updates
Chief Information Officer recently sold Mex$4.2m worth of stock Nov 22
Lead Independent Director recently sold Mex$4.4m worth of stock Nov 15
Third quarter 2024 earnings released: US$0.88 loss per share (vs US$0.73 loss in 3Q 2023) Nov 08
Guardant Health, Inc. Revises Revenue Guidance for the Year 2024 Nov 07
Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director Oct 25
Guardant Health, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 16 Meer updates bekijken
Chief Information Officer recently sold Mex$4.2m worth of stock Nov 22
Lead Independent Director recently sold Mex$4.4m worth of stock Nov 15
Third quarter 2024 earnings released: US$0.88 loss per share (vs US$0.73 loss in 3Q 2023) Nov 08
Guardant Health, Inc. Revises Revenue Guidance for the Year 2024 Nov 07
Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director Oct 25
Guardant Health, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 16 Guardant Health, Inc. has filed a Follow-on Equity Offering in the amount of $400 million. Aug 24
Second quarter 2024 earnings released: US$0.84 loss per share (vs US$0.67 loss in 2Q 2023) Aug 09
Guardant Health, Inc. Raises Earnings Guidance for the Full Year of 2024 Aug 08
Guardant Health, Inc.'s FDA-Appoints Shield™? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer Aug 02
High number of new directors Aug 01
Guardant Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 25
Guardant Health, Inc. Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-In-Class Performance Jul 23
Guardant Health, Inc. Announces the Appointment of Dr. Manuel Hidalgo Medina to Board of Directors Jul 19
Guardant Health Introduces New Guardant360 Tissuenext Test with Nearly 500 Biomarkers to Identify More Treatment Options for Patients with Advanced Cancer Jun 05 Guardant Health, Inc. Announces FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
First quarter 2024 earnings released: US$0.94 loss per share (vs US$1.30 loss in 1Q 2023) May 11
Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024 May 11
Guardant Health, Inc., Annual General Meeting, Jun 12, 2024 Apr 28
Guardant Health, Inc. to Report Q1, 2024 Results on May 09, 2024 Apr 20
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting Apr 03
Chief Information Officer recently bought Mex$656k worth of stock Mar 26
Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer Mar 14
Full year 2023 earnings released: US$4.28 loss per share (vs US$6.41 loss in FY 2022) Feb 24
Guardant Health, Inc. Provides Earnings Guidance for the Year 2024 Feb 23 Guardant Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024
Guardant Health, Inc. Announces Executive Changes Jan 02
Guardant Health, Inc. Announces Tentative Date of FDA Advisory Panel Review of Shield(TM) Blood Test Dec 20
Guardant Health, Inc. to Appeal Federal District Court Verdict Nov 17
Guardant Health, Inc. Provides Revenue Guidance for Full Year 2023 Nov 07
Guardant Health, Inc. Announces Initial Results from the PEGASUS Trial Oct 24
Guardant Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 17
Guardant Health, Inc. Receives Coverage for Guardant Reveal from Geisinger Health Plan Sep 07
Guardant Health, Inc. Receives Regulatory Approval in Japan for Guardant360®? CDx as Companion Diagnostic to ENHERTU®? for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations Sep 06
Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023 Aug 04
Second quarter 2023 earnings released: US$0.67 loss per share (vs US$2.25 loss in 2Q 2022) Aug 04
Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research Aug 03
Guardant Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 13 Guardant Health, Inc. Announces Reimbursement Approval of Guardant360 CDx Liquid Biopsy Test in Japan Jul 06
Guardant Health, Inc.(NasdaqGS:GH) dropped from Russell 1000 Dynamic Index Jun 25
High number of new directors Jun 16 Guardant Health, Inc. has completed a Follow-on Equity Offering in the amount of $350 million. May 24
First quarter 2023 earnings released: US$1.30 loss per share (vs US$1.21 loss in 1Q 2022) May 12
High number of new directors May 12
Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023 May 11
Guardant Health, Inc. Announces Management Changes May 09
High number of new directors Apr 25
Guardant Health, Inc. Initiates New Study to Examine the Impact of Shield Blood Test to Increase Screening Compliance for Colorectal Cancer Feb 16
Guardant Health, Inc. Receives Coverage from UnitedHealthcare for Guardant360® CDx Blood Test as Companion Diagnostic in Advanced Lung and Breast Cancer Feb 09
Guardant Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 02
Guardant Health Introduces Guardant Galaxytm Suite of Advanced Ai Analytics to Enhance Its Portfolio of Cancer Tests and Accelerate Biomarker Discovery Feb 01
Guardant Health, Inc. Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Menarini Group’S ORSERDU for Treatment of Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer Jan 31
Guardant Health and the Royal Marsden NHS Foundation Trust Partner on Highly Anticipated TRACC Part C Trial to Use Guardant Reveal(Tm) Blood Test to Help Guide Treatment Decisions in Colorectal Cancer Jan 21
Guardant Health, Inc. to Showcase New Data at ASCO GI 2023 Demonstrating Utility of its Blood Tests for Patients with Gastrointestinal Cancers Jan 18
Guardant Health, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 Jan 11
Guardant Health, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 Jan 10
Guardant Health, Inc. and Susan G. Komen(R) Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit from Additional Monitoring or Therapy Dec 22
Guardant Health Announces Positive Results from Pivotal ECLIPSE Study Evaluating A Blood Test for the Detection of Colorectal Cancer Dec 16
Chief Information Officer recently sold Mex$3.1m worth of stock Nov 18
Third quarter 2022 earnings released: US$1.58 loss per share (vs US$1.06 loss in 3Q 2021) Nov 05
Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022 Nov 04
Guardant Health, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 11
Guardant Health Introduces GuardantINFINITY Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner Sep 10
Guardant Health, Inc. to Showcase New Data At ESMO 2022 Demonstrating Utility of Its Portfolio of Blood Tests for Advanced-Stage Cancer Patients Sep 07
Senior Vice President of People recently sold Mex$4.3m worth of stock Aug 16
Guardant Health, Inc. Receives FDA Approval for Guardant360® Cdx as Companion Diagnostic for Daiichi Sankyo and Astrazeneca’S Enhertu® for Treatment of Nsclc Patients with Activating Her2 Mutations Aug 13
Second quarter 2022 earnings released: US$2.25 loss per share (vs US$0.96 loss in 2Q 2021) Aug 05
Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022 Aug 05
Guardant Health, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 14
Guardant Health, Inc. Appoints Steve E. Krognes as Class III Director, Effective June 30, 2022 Jul 08
Guardant Health, Inc. Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-Of-Its Kind Prospective Study At Digestive Disease Week 2022 May 22
Guardant Health, Inc. Provides Revenue Guidance for the Year 2022 May 06
Guardant Health, Inc. Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults May 03
Guardant Health, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 14
Guardant Health, Inc. Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American Association for Cancer Research Annual Meeting Apr 12
Guardant Health, Inc. Announces That Stanley Meresman Will Not Stand for Re-Election to the Company’s Board of Directors Mar 03
Guardant Health, Inc. Provides Revenue Guidance for the Year 2022 Feb 24
Guardant Health, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 02
Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium Jan 20
Guardant Health, Inc. Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults Jan 19
Guardant Health Reaches Target Enrollment of 12,750 Patients in Eclipse Pivotal Study for Its Lunar-2 Blood Test to Detect Colorectal Cancer Dec 19
High number of new directors Dec 03
Guardant Health, Inc. Reaffirms Revenue Guidance for the Year 2021 Aug 08
TwinStrand Biosciences, Inc. Announces Filing of Patent Infringement Lawsuit against Guardant Health, Inc Aug 05
Guardant Health Expands Guardant360® Portfolio with New Tests for Treatment Response Monitoring and Complete Genomic Profiling Jun 23
Guardant Health, Inc. Presents Data At 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients with Early-Stage Cancer Jun 05
Guardant Health, Inc. Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer May 29
Guardant360 CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations May 22
Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2021 May 07
Full year 2020 earnings released: US$2.60 loss per share (vs US$0.83 loss in FY 2019) Feb 26
Revenue beats expectations Feb 26
Guardant Health, Inc. Launches Guardant Reveal™ Liquid Biopsy Test for Residual Disease and Recurrence Monitoring in Patients with Early-Stage Colorectal Cancer Feb 18 Rendement voor aandeelhouders GH * MX Healthcare MX Markt 7D 0% 3.4% 1.2% 1Y n/a -30.7% -11.1%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe GH * presteerde ten opzichte van de MX Healthcare.
Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe GH * presteerde ten opzichte van de MX markt.
Prijsvolatiliteit Is GH *'s price volatile compared to industry and market? GH * volatility GH * Average Weekly Movement n/a Healthcare Industry Average Movement 7.3% Market Average Movement 4.0% 10% most volatile stocks in MX Market 6.2% 10% least volatile stocks in MX Market 2.7%
Stabiele aandelenkoers: De aandelenkoers van GH * is de afgelopen 3 maanden volatiel geweest in vergelijking met de MX markt.
Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van GH * in het afgelopen jaar te bepalen.
Over het bedrijf Guardant Health, Inc., een oncologisch precisiebedrijf, levert bloed- en weefseltests, datasets en analyses in de Verenigde Staten en daarbuiten. Het bedrijf biedt Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, een geïntegreerde software-gebaseerde oplossing ontworpen voor klinische en biofarmaceutische klanten om patiënten getest met assays met bruikbare veranderingen te verbinden met potentieel relevante klinische studies; GuardantOMNI Test voor kanker in een gevorderd stadium; en GuardantINFORM, een in-silico onderzoeksplatform voor tumor evolutie en resistentie tegen behandelingen in verschillende biomarker-gedreven kankers. Het biedt Shield Test; Guardant Reveal Test voor adjuvante behandelingsselectie bij kankerpatiënten in een vroeg stadium; Smart Liquid Biopsy Platform; en Guardant Galaxy, een AI-ondersteund digitaal pathologieplatform dat helpt bij het verbeteren van de detectie van biomarkers voor kanker.
Meer tonen Guardant Health, Inc. Samenvatting Hoe verhouden de winst en inkomsten van Guardant Health zich tot de beurswaarde? GH * fundamentele statistieken Marktkapitalisatie Mex$93.98b Inkomsten(TTM ) -Mex$10.62b Inkomsten(TTM ) Mex$14.35b
6.6x P/S-verhouding
-8.9x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) GH * resultatenrekening (TTM ) Inkomsten US$692.26m Kosten van inkomsten US$274.72m Brutowinst US$417.53m Overige uitgaven US$929.94m Inkomsten -US$512.41m
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -4.15 Brutomarge 60.31% Nettowinstmarge -74.02% Schuld/Eigen Vermogen Verhouding -1,900.1%
Hoe presteerde GH * op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2025/01/11 21:16 Aandelenkoers aan het einde van de dag 2024/12/02 00:00 Inkomsten 2024/09/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Guardant Health, Inc. wordt gevolgd door 30 analisten. 22 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Michael Ryskin BofA Global Research Derik de Bruin BofA Global Research Mark Massaro BTIG
Toon 27 meer analisten 
